An Open-Label, Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose- Agarose Macrobeads in the Treatment of Patients With Castration-Resistant Prostate Cancer Resistant to Docetaxel
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor volume
16 months
Yes
Barry H Smith, MD
Principal Investigator
The Rogosin Institute
United States: Food and Drug Administration
1003010955
NCT01174368
June 2010
December 2013
Name | Location |
---|---|
The Rogosin Institute | New York, New York 10021 |